{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T06:05:36Z","timestamp":1777442736056,"version":"3.51.4"},"reference-count":30,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2015,6,29]],"date-time":"2015-06-29T00:00:00Z","timestamp":1435536000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0132267","type":"journal-article","created":{"date-parts":[[2015,6,29]],"date-time":"2015-06-29T14:35:15Z","timestamp":1435588515000},"page":"e0132267","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":13,"title":["t-Darpp Promotes Enhanced EGFR Activation and New Drug Synergies in Her2-Positive Breast Cancer Cells"],"prefix":"10.1371","volume":"10","author":[{"given":"Erin C.","family":"Denny","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan E.","family":"Kane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2015,6,29]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3322\/caac.20107","article-title":"Global cancer statistics","volume":"61","author":"A Jemal","year":"2011","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1016\/S0140-6736(11)61351-2","article-title":"Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis","volume":"378","author":"MH Forouzanfar","year":"2011","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1634\/theoncologist.2008-0230","article-title":"The HER-2 receptor and breast cancer: Ten years of targeted anti\u2013HER-2 therapy and personalized medicine","volume":"14","author":"JS Ross","year":"2009","journal-title":"Oncologist"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/stem.160413","article-title":"The HER-2\/neu oncogene in breast cancer: Prognostic factor, predictive factor, and target for therapy","volume":"16","author":"JS Ross","year":"1998","journal-title":"Stem Cells"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.1038\/sj.onc.1210379","article-title":"Trastuzumab: triumphs and tribulations","volume":"26","author":"R Nahta","year":"2007","journal-title":"Oncogene"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1200\/JCO.20.3.719","article-title":"Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer","volume":"20","author":"CL Vogel","year":"2002","journal-title":"J Clin Oncol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/cyto.a.10095","article-title":"Development of Herceptin resistance in breast cancer cells","volume":"57","author":"T Kute","year":"2004","journal-title":"Cytometry"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.ccr.2007.08.030","article-title":"A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer","volume":"12","author":"K Berns","year":"2007","journal-title":"Cancer Cell"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/path.1003","article-title":"EGFR family expression in breast carcinomas. c-erbB-2 and c-erbB-4 receptors have different effects on survival","volume":"196","author":"Z Suo","year":"2002","journal-title":"J Pathol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1067\/msy.2003.32","article-title":"Prognostic value of the combination of epidermal growth factor receptor and c-erbB-2 in breast cancer","volume":"133","author":"S Tsutsui","year":"2003","journal-title":"Surgery"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1200\/JCO.2005.09.055","article-title":"Relationship of epidermal growth factor receptor expression to erbB-2 signaling activity and prognosis in breast cancer patients","volume":"23","author":"MP DiGiovanna","year":"2005","journal-title":"J Clin Oncol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1038\/bjc.2012.85","article-title":"Increased signalling of EGFR and IGF1R, and deregulation of PTEN\/PI3K\/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas","volume":"106","author":"A Gallardo","year":"2012","journal-title":"Br J Cancer"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s10549-004-7715-1","article-title":"Differential sensitivities of trastuzumab (Herceptin)-resistant human breast cancer cells to phosphoinositide-3 kinase (PI-3K) and epidermal growth factor receptor (EGFR) kinase inhibitors","volume":"91","author":"C Chan","year":"2005","journal-title":"Breast Cancer Res Treat"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1007\/s10637-010-9415-5","article-title":"Synergistic interaction between trastuzumab and EGFR\/HER-2 tyrosine kinase inhibitors in HER-2 positive breast cancer cells","volume":"29","author":"N O\u2019Donovan","year":"2011","journal-title":"Invest New Drugs"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1158\/1078-0432.CCR-03-0244","article-title":"Treatment of HER-2\/neu Overexpressing Breast Cancer Xenograft Models with Trastuzumab (Herceptin) and Gefitinib (ZD1839): Drug Combination Effects on Tumor Growth, HER-2\/neu and Epidermal Growth Factor Receptor Expression, and Viable Hypoxic Cell Fraction","volume":"10","author":"C Warburton","year":"2004","journal-title":"Clin Cancer Res"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1093\/jnci\/djk151","article-title":"Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy","volume":"99","author":"G Arpino","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"e6220","DOI":"10.1371\/journal.pone.0006220","article-title":"Darpp-32 and its truncated variant t-Darpp have antagonistic effects on breast cancer cell growth and Herceptin resistance","volume":"4","author":"L Gu","year":"2009","journal-title":"PLoS ONE"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"4564","DOI":"10.1158\/1078-0432.CCR-08-0121","article-title":"Expression of t-DARPP mediates trastuzumab resistance in breast cancer cells","volume":"14","author":"A Belkhiri","year":"2008","journal-title":"Clin Cancer Res"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s10549-009-0364-7","article-title":"Both t-Darpp and DARPP-32 can cause resistance to trastuzumab in breast cancer cells and are frequently expressed in primary breast cancers","volume":"120","author":"S Hamel","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"4504","DOI":"10.1158\/0008-5472.CAN-12-1119","article-title":"Regulation of ERBB2 receptor by t-DARPP mediates trastuzumab resistance in human esophageal adenocarcinoma","volume":"72","author":"J Hong","year":"2012","journal-title":"Cancer Res"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/310503a0","article-title":"DARPP-32, a dopamine-regulated neuronal phosphoprotein, is a potent inhibitor of protein phosphatase-1","volume":"310","author":"HC Hemmings","year":"1984","journal-title":"Nature"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/45251","article-title":"Phosphorylation of DARPP-32 by Cdk5 modulates dopamine signalling in neurons","volume":"402","author":"JA Bibb","year":"1999","journal-title":"Nature"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1002\/cncr.11654","article-title":"Overexpression of the 32-kilodalton dopamine and cyclic adenosine 3\u2032,5\u2032-monophosphate-regulated phosphoprotein in common adenocarcinomas","volume":"98","author":"A Beckler","year":"2003","journal-title":"Cancer"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1186\/1476-4598-9-240","article-title":"t-DARPP regulates phosphatidylinositol-3-kinase-dependent cell growth in breast cancer","volume":"9","author":"B Vangamudi","year":"2010","journal-title":"Molec Cancer"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1007\/s00280-003-0728-3","article-title":"In vitro effects of trastuzumab and vinorelbine in trastuzumab-resistant breast cancer cells","volume":"53","author":"R Nahta","year":"2004","journal-title":"Cancer Chemo Pharmacol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug combination studies and their synergy quantification using the Chou-Talalay method","volume":"70","author":"T-C Chou","year":"2010","journal-title":"Cancer Res"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1615\/CritRevOncog.v17.i1.20","article-title":"Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: Mechanisms and clinical implications","volume":"17","author":"BN Rexer","year":"2012","journal-title":"Crit Rev Oncog"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1158\/0008-5472.CAN-10-1872","article-title":"Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers","volume":"71","author":"R Ghosh","year":"2011","journal-title":"Cancer Res"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"R121","DOI":"10.1186\/bcr3067","article-title":"Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers\u2014role of estrogen receptor and HER2 reactivation","volume":"13","author":"YC Wang","year":"2011","journal-title":"Breast Cancer Res"},{"key":"ref30","first-page":"7184","article-title":"The tyrosine kinase inhibitor ZD1839 (\u201cIressa\u201d) inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells","volume":"61","author":"MM Moasser","year":"2001","journal-title":"Cancer Res"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0132267","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,20]],"date-time":"2018-10-20T08:10:58Z","timestamp":1540023058000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0132267"}},"subtitle":[],"editor":[{"given":"Ming","family":"Tan","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2015,6,29]]},"references-count":30,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2015,6,29]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0132267","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,29]]}}}